Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care
Liver International · 2025-04 · 45 (4)
DOI: 10.1111/liv.16119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 07.10.2024. Verfasst von Zobair M Younossi und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Primary Health Care, Mass Screening, Diabetes Mellitus, Type 2, Fatty Liver. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Several scientific associations recommend a sequential combination of non‐invasive tests (NITs) to identify high‐risk MASLD patients but their cost‐effectiveness is unknown.
Methods
A cost‐utility model was developed to assess the incremental cost‐effectiveness ratio (ICER) of recommended screening strategies for patients with clinically suspected MASLD, specifically those with type 2 diabetes (T2D) and obesity with multiple cardiometabolic risk factors which will be initiated in primary care. Six screening strategies were assessed, using either vibration‐controlled transient elastography (VCTE) or the enhanced liver fibrosis (ELF) test as a second‐line test following an initial Fibrosis‐4 (FIB‐4) assessment as the first line NIT. The model included treatment effects of resmetirom for metabolic dysfunction‐associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.
Results
All screening strategies for high‐risk MASLD in US incurred additional costs compared to no screening, ranging from $13 587 to $14 730 per patient with T2D and $14 274 to $15 661 per patient with obesity. However, screening reduced long‐term costs, ranging from $22 150 to $22 279 per patient with T2D and $13 704 to $13 705 per patient with obesity, compared to $24 221 and $14 956 for no screening, respectively. ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24 992 per QALY for patients with obesity. While ICERs were influenced by VCTE availability, they remained cost‐effective when using ELF as the second‐line test. Our findings remain robust across a range of key parameters.
Conclusions
Screening for high‐risk MASLD is cost‐effective according to recent guidelines. Implementing these screening strategies in primary care should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Global NASH Council, Washington, DC, USA.
- Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
- Center for Outcomes Research in Liver Diseases, Washington, DC, USA.
Zitieren
APA
Younossi, Z. M., Paik, J. M., Henry, L., Stepanova, M., & Nader, F. (2025). Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care. Liver International, 45(4). https://doi.org/10.1111/liv.16119
Vancouver
Younossi ZM, Paik JM, Henry L, Stepanova M, Nader F. Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care. Liver International. 2025;45(4). doi:10.1111/liv.16119
BibTeX
@article{Younossi2025,
author = {Younossi, Zobair M and Paik, James M and Henry, Linda and Stepanova, Maria and Nader, Fatema},
title = {Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care},
journal = {Liver International},
year = {2025},
volume = {45},
number = {4},
doi = {10.1111/liv.16119}
}
EUVIMED